ReCor Paradise Catheter
Recor Medical, Inc. · Decision date Sep 11, 2025
What did the FDA decide?
FDA records P220023/S009 as a supplement to PMA P220023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 11, 2025.
FDA approval order statement
automated processes for determining transducer measurements and programming parameters into the catheter EEPROM
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 11, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220023/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Recor Medical, Inc.
- Product code
- QYI
- Decision code
- OK30
- Decision date
- Sep 11, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Recor Medical, Inc.
- Product code
- QYI
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220023/S009 received
Application receipt date recorded by FDA.
P220023/S009 · FDA decision
30-Day Notice
P220023/S012 · Related supplement
Paradise Ultrasound Renal Denervation System (Paradise System); Paradise Catheter
P220023/S011 · Related supplement
Paradise Ultrasound Renal Denervation System (Paradise System)
Timeline entries are records held by MedtechLedger for P220023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Recor Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Recor Medical, Inc. | PMA supplement | Aug 13, 2026 | FDA |
Explore the linked device profile
Other records with product code QYI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S017 | Medtronic, Inc. | PMA supplement | Jul 16, 2026 | FDA |
Symplicity Spyral Renal Denervation CatheterP220026/S016 | Medtronic, Inc. | PMA supplement | Mar 25, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Feb 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Recor Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1049 Elwell Ct., Palo Alto, CA, 94303
Sources and methodology
- Original FDA record: P220023/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


